Preventive Pharmacotherapy of Headache Disorders by Jes OlesenPreventive Pharmacotherapy of Headache Disorders by Jes Olesen

Preventive Pharmacotherapy of Headache Disorders

EditorJes Olesen, Stephen D Silberstein, Peer Tfelt-hansen

Hardcover | April 29, 2004

Pricing and Purchase Info

$419.06 online 
$742.50 list price save 43%
Earn 2,095 plum® points

Prices and offers may vary in store


Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores


Most of the familiar headache drugs are used to stop a headache attack that is already in progress, or about to begin. However, there is now a growing body of research aimed at developing medications that can be taken on a regular basis to prevent headcahes from starting. These drugs will betargetted at patients whose headaches are frequent or who get their headaches at predicatble times. This book reviews the potential for prophylactic treatment of headache. It provides most of the existing evidence in the field of pharmaco-prophylaxis of migraine and other chronic headaches and maythus, serve as a platform for new initiatives in the field. The book reviews the research into the pharmacological mechanisms involved, the classes of drugs in development and the clinical trials methodology. The editors have gathered together the leading international experts to produce a book that will appeal neurologists caring for headache patients, researchers in the field and those based in the pharmaceutical industry.
Jes Olesen is in the Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark. Stephen D Silberstein is Director, Jefferson Headache Center, Thomas Jeffersen University, Philadelphia, Pennsylvania, USA. Peer Tfelt-Hansen is in the Department of Neurology, Glostrup Hospital, Denmark.
Title:Preventive Pharmacotherapy of Headache DisordersFormat:HardcoverDimensions:292 pages, 9.45 × 6.61 × 0.82 inPublished:April 29, 2004Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0198528442

ISBN - 13:9780198528449


Table of Contents

Section I - Methodology of prophylactic trials1. Peter J Goadsby: Principles of preventive pharmacotherapy in primary headache2. Henry J McQuay: Methodology and implementation of systematic reviews3. Doris Irene Stenver: Adverse events, equally important as efficacy as an outcome parameter?4. Peer Tfelt-Hansen: Methodology of prophylactic trials: discussion summarySection II - Prophylactic drugs I5. Peer Tfelt-Hansen: Key issues in the methodology of prophylactic migraine trials6. M Lanteri-Minet, H Aalchaar, G Besson, F Bille-Turc, F Brudon, A Donnet, J Valance and JL Gastaut: Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France7. W Hester Visser, William Malbecq, Kim Strohmaier, Christopher Lines and Scott A Reines: Preventive treatment of migraine headache with rofecoxib8. Achim Frese, Katrin Frese, Sonja Schwaag, Alexandra Rahmann, Ingo-W Husstedt and Stefan Evers: Prophylactic treatment and course of the disease in headache associated with sexual activity9. Stephen D Silberstein: Propylactic drugs I: discussion summarySection III - Prophylactic drugs II10. Hans-Christoph Diener and Volker Limmroth: Prevention of migraine: betablockers and amine agonists: efficacy11. Stephen D Silberstein: Antiepileptic drugs in migraine prevention12. H Steve White: Mechanism(s) of action of the antiepileptic drugs Valproic Acid, Gabapentin, and Topiramate: implications for the prophylactic management of migraine13. J Pascual, M Sanchez del Rio, V Mateos, JM Lainez, J Hernandez-Gallego, R Leira and MD Jimenez: Experience with topiramate in patients with refractory migraine14. Reto M Agosti and Sonja Eugster: Topiramate in a selective group of therapy refractory headache patients15. Jean Schoenen: Prophylactic drugs II: discussion summarySection IV - Prophylactic Drugs III16. Lars Bendtsen: Efficacy of antidepressants in headache prophylaxis17. Elliott Richelson: Antidepressants: mechanisms of action18. Jean Schoenen, Laura Di Clemente and Gianluca Coppola: Other prophylactic anti-migraine agents: riboflavin feverfew, magnesium, botulinum toxin and calcium antagonists19. Isin Baral Kulaksizoglu, Sibel Cakir and Mustafa Ertas: Treatment of chronic tension type headache with mirtazapine20. Stewart J Tepper, Marcelo E Bigal, Fred D Sheftell and Alan Rapoport: Botulinum toxin type A in the treatment of refractory headache21. Sonja Schwaag, Alexandra Rahmann, Achim Frese, Ingo-W Husstedt, Juliane Vollmer-Haase and Stefan Evers: Botulinum toxin A in the prophylaxis of migraine - a double-blind, placebo-controlled, randomised study comparing frontal and cervical injection22. Stephen Silberstein, M Alan Stiles, Cheryl Gebeline-Myers and Kathleen Coughlin Bradley: Description of a prospective, multicenter observational study of headache treatment with Botulinum toxin type A: the program to assess treatment strategies (PATS) registry23. M Cui and KR Aoki: Mechanisms of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing24. Gabriella Coloprisco, Sergio De Filippis, Pier Giorgio Santi, Guiseppe Fiore, Anna Rodio and Paolo Martelletti: Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment25. Yoko Hibi, Hisaka Igarashi, Fumihiko Sakai: Prophylactic treatment of migraine with lomerizine hydrochloride26. Peter J Goadsby: Prophylactic drugs III: discussion summarySection V - New Targets I27. Sally Bolton and Celestine O'Shaughnessy: Antagonising peripheral sensitisation in migraine28. RG Hill, MJ Cumberbatch and DJ Williamson: New possibilities for antimigraine therapy via 5-HT receptors?29. B Schaerlinger, P Hickel, N Etienne and L Maroteaux: Dihydroergotamine interaction with 5-HT2 receptors and its relevance to migraine30. Lars Jacob Stovner, Erling Tronvik, Harald Schrader, Grethe Helde, Trond Sand and Gunnar Bovim: Migraine prophylaxis with drugs influencing the angiotensin system31. Alan M Rapoport, Marcelo E Bigal, Stewart J Tepper, Fred D Sheftell: Naratriptan in the preventive treatment of refractory chronic migraine32. A Pradalier, M Lanteri-Minet, Ch Lucas and G Geraud: PROMISE study (PROphylaxis of MIgraine with SEglor)33. M Hamon, S Bourgoin and L Lanfumey: Serotinin receptors and migraine prophylaxis - the case of dihydroergotamine34. Richard Peatfeld: What is the mechanism of action of ACE inhibitors in migraine prophylaxis?35. Dominique Valade: Triptans with methysergide36. Jes Olesen: New Targets I: discussion summarySection VI - new targets II37. Paul JLM Strijbos and Andrew A Parsons: Nitric oxide and its signalling pathways: a rich source of potential targets for migraine therapy38. Henri Doods: Calcitonin gene related peptide and migraine39. Christina Kruuse and Joseph A Beavo: Phosphodiesterases, cyclic nucleotides, and their role in migraine40. Stefan Evers, Achim Frese, Sonja Schwaag, Reiner Luttmann and Ingo-W Husstedt: The prostaglandin-E1-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia41. Ray Hill: New targets II: discussion summary